Evidence map›Paper›PMID 40986428›Full record

ArticleCancer discovery2026

EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.

Alberto Diaz-Jimenez, Emily G Shuldiner, Kalman Somogyi, Karen Y Shih, Óscar González-Velasco, Mulham Najajreh, Stewart Kim, Filiz Akkas, Christopher W Murray, Laura Andrejka and 10 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alberto Diaz-Jimenez *Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0002-8311-2413
Emily G Shuldiner *Department of Biology, Stanford University, Stanford, California.ORCID 0000-0002-5018-0500
Kalman SomogyiDivision of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8377-9766
Karen Y ShihDepartment of Biology, Stanford University, Stanford, California.ORCID 0000-0001-7669-1643
Óscar González-VelascoDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-5054-8635
Mulham NajajrehDivision of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-3355-8866
Stewart KimCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-7196-0541
Filiz AkkasDivision of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0003-9676-0951
Christopher W MurrayCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-7027-892X
Laura AndrejkaDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-2202-5626
Min K TsaiCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-4732-4259
Benedikt BrorsDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-5940-3101
Ilse HofmannCore Facility Antibodies, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-3586-5050
Smruthy SivakumarFoundation Medicine Inc., Boston, Massachusetts.ORCID 0000-0001-7790-5615
Saumya D SisoudiyaFoundation Medicine Inc., Boston, Massachusetts.ORCID 0000-0001-7276-8084
Ethan S SokolFoundation Medicine Inc., Boston, Massachusetts.ORCID 0000-0002-5480-8473
Hongchen CaiDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-5921-5773
Dmitri A PetrovDepartment of Biology, Stanford University, Stanford, California.ORCID 0000-0002-3664-9130
Monte M WinslowCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-5730-9573
Rocio SotilloDivision of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-0855-7917

Funding

Medical Scientist Training ProgramT32GM145402 · NIGMS · STANFORD UNIVERSITY · PI Katrin F. Chua · 2022 to 2026
$10.0M
Unraveling mechanisms of tumor suppression in lung cancerR01CA234349 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2019 to 2023
$2.4M
Anne T. and Robert M. Bass Stanford Graduate FellowshipChan Zuckerberg BiohubDeutsches Krebsforschungszentrum (DKFZ)DZL Academy Mobility GrantGerman Center for Lung Research DZL004B4Ministry of Science, Research and Arts of the State of Baden-Wuerttemberg, GermanyNational Cancer Institute (NCI) CA234349National Institutes of Health (NIH) T32GM145402National Natural Science Foundation of China 82372670National Science Foundation Graduate Research Fellowship Program (GRFP)NCI NIH HHS R01 CA234349Tobacco-Related Disease Research Program (TRDRP) T33DT6556Worldwide Cancer Research (WCR) 22-0197
6 · The paper itself

Abstract

Diverse fusions of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) are oncogenic drivers in lung adenocarcinoma. EML4-ALK variants have distinct breakpoints within EML4, but their functional differences remain poorly understood. In this study, we use somatic genome editing to generate autochthonous mouse models of EML4-ALK-driven lung tumors and show that variant 3 (V3) is more oncogenic than variant 1 (V1). By using multiplexed genome editing and quantifying the effects of 29 putative tumor-suppressor genes on V1- and V3-driven lung cancer growth, we show that many tumor-suppressor genes have variant-specific effects on tumorigenesis. Pharmacogenomic analyses further suggest that tumor genotype can influence therapeutic responses. Analysis of human EML4-ALK-positive lung cancers also identified variant-specific differences in their genomic landscapes. These findings suggest that EML4-ALK variants behave more like distinct oncogenes than a uniform entity and highlight the dramatic impact of oncogenic fusion partner proteins and coincident tumor-suppressor gene alterations on the biology of oncogenic fusion-driven cancers. SIGNIFICANCE: EML4-ALK-driven lung cancer is treated as a uniform disease despite the presence of distinct fusion variants in patients. Our findings show that EML4-ALK variants are functionally distinct, which may have implications for the treatment of this cancer type and highlights the need to consider differences among variants of other oncogenic fusions.

Indexed as

CarcinogenesisLung NeoplasmsOncogene Proteins, FusionAdenocarcinoma of LungAnimalsHumansMiceEML4-ALK fusion protein, humanOncogene Proteins, Fusion

Identifiers

PMID40986428
PMCPMC12479099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.